Intermittent Hormone Therapy: What Is Its Place in Clinical Practice? Claude C. Schulman  European Urology Supplements  Volume 8, Issue 12, Pages 852-856 (December 2009) DOI: 10.1016/j.eursup.2009.07.005 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Results of a meta-analysis of 10 phase 2 studies on intermittent hormone therapy (IHT) showing the percentage of patients off treatment at 2 yr, overall survival, and the percentage of patients progressing to castration-resistant prostate cancer (CRPC) separately for patients with localised prostate cancer (PCa), patients with a prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or radiotherapy (RT), and patients with node-positive (N+) or metastatic (M+) PCa [18]. European Urology Supplements 2009 8, 852-856DOI: (10.1016/j.eursup.2009.07.005) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Percentage of patients reporting side effects at least once in the South European Uroncological Group (SEUG) trial [19]. HT=hormone therapy; IHT=intermittent hormone therapy. European Urology Supplements 2009 8, 852-856DOI: (10.1016/j.eursup.2009.07.005) Copyright © 2009 European Association of Urology Terms and Conditions